<SEC-DOCUMENT>0001019687-15-001380.txt : 20150410
<SEC-HEADER>0001019687-15-001380.hdr.sgml : 20150410
<ACCEPTANCE-DATETIME>20150409210626
ACCESSION NUMBER:		0001019687-15-001380
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20150410
DATE AS OF CHANGE:		20150409

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-201334
		FILM NUMBER:		15762408

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>aethlon_424b3.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>&nbsp;Registration
No. 333-201334</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT NO. 4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(to prospectus dated January 28, 2015)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">24,750,000 Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement relates to the
prospectus dated January 28, 2015 relating to the following common stock that may be sold from time to time by the selling stockholders
identified in the prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 113px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 38px; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">11,000,000 shares of common stock; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 113px">&nbsp;</TD>
    <TD STYLE="width: 38px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">13,750,000 shares of common stock underlying common stock purchase warrants at an exercise price of $0.30 per share.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of the common stock covered by the prospectus
is being sold by the selling stockholders for their own account. We will not receive any proceeds from the sale of these shares
other than proceeds, if any, from the exercise of warrants to purchase shares of our common stock. If all of the warrants are exercised
for cash, we will receive a total of $4,125,000 in gross proceeds, which we expect to use for general corporate purposes. We cannot
assure you that any warrants will be exercised for cash. The selling stockholders may offer and sell the shares covered by the
prospectus at prevailing prices quoted on the OTCQB Marketplace or at privately negotiated prices. The selling stockholders may
sell the shares directly or through underwriters, brokers or dealers. The selling stockholders will bear any applicable sales commissions,
transfer taxes and similar expenses. We will pay all other expenses incident to the registration of the shares. See &ldquo;Plan
of Distribution&rdquo; on page 28 of the prospectus for more information on this topic. The selling stockholders originally purchased
the common stock and warrants from us on December 2, 2014, for an aggregate price of $3,300,000. The prospectus covers the sale
of those securities by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are filing this prospectus supplement
to supplement and amend the information previously included in the prospectus with the information contained in our Current Report
on Form 8-K filed with the Securities and Exchange Commission on April 9, 2015. Accordingly, we have attached our Current Report
on Form 8-K to this prospectus supplement. You should read this prospectus supplement together with the prospectus and the prospectus
supplements filed on February 10, 2015, March 16, 2015 and April 7, 2015, which are to be delivered with this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is quoted on the OTCQB
Marketplace under the symbol &ldquo;AEMD.&rdquo; On April 6, 2015, the last quoted sale price of our common stock as reported on
the OTCQB Marketplace was $0.24 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our securities involves
significant risks, including those set forth in the &ldquo;Risk Factors&rdquo; section of the prospectus beginning at page 4.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NEITHER THE SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THE PROSPECTUS OR THIS OR
ANY OTHER PROSPECTUS SUPPLEMENT IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
April 10, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM 8-K</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CURRENT REPORT</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Date of Report (Date of earliest event reported):
April 6, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of
        incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">000-21846</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(IRS Employer Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">9635 Granite Ridge Drive, Suite 100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">92123</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Former name or former address, if changed since
last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 97%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This Form 8-K and other reports filed by us
from time to time with the Securities and Exchange Commission contain or may contain forward-looking statements and information
that are based upon beliefs of, and information currently available to, our management as well as estimates and assumptions made
by our management. When used in such filings, the words &quot;anticipate,&rdquo; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot;
&quot;future,&quot; &quot;intend,&quot; &quot;plan&quot; or the negative of these terms and similar expressions as they relate
to us or our management identify forward-looking statements. Such statements reflect our current view with respect to future events
and are subject to risks, uncertainties, assumptions and other factors relating to our industry, our operations and results of
operations and any businesses that we may acquire. Should one or more of these risks or uncertainties materialize, or should the
underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected,
intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the
forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">ITEM 8.01</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt">OTHER EVENTS<FONT STYLE="font-weight: normal">.</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On April 9, 2015, Aethlon Medical, Inc. (&ldquo;we&rdquo;)
issued a press release announcing that we had submitted a Humanitarian Use Device (&ldquo;HUD&rdquo;) submission to the U.S. Food
and Drug Administration (&ldquo;FDA&rdquo;) to support market clearance of the Aethlon Hemopurifier&reg; as a treatment for Ebola
virus. If the HUD application is designated by the FDA, we then may submit a Humanitarian Device Exemption marketing application
to the Center for Devices and Radiological Health for marketing review. We cannot assure you that we will receive approval to market
the Hemopurifier as a treatment for Ebola virus. A copy of the press release is filed as Exhibit 99.1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM 9.01</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FINANCIAL STATEMENTS AND EXHIBITS.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d) EXHIBITS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 10%; text-align: left; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXHIBIT<BR>NO.</FONT></TD>
    <TD STYLE="width: 90%; text-align: left; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">DESCRIPTION</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Press Release dated April 9, 2015</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt">AETHLON MEDICAL, INC.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:&nbsp;<U>/s/ James B. Frakes</U></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">James B. Frakes</FONT></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Dated: April 9, 2015</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->







<P STYLE="margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 54pt; width: 144.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aethlon Medical Announces Ebola Humanitarian
Use Device Submission to the FDA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SAN DIEGO, April 9, 2015 /PRNewswire/ --Aethlon Medical, Inc. (OTCQB:AEMD),
a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has submitted
a Humanitarian Use Device submission to the United States Food and Drug Administration (FDA) to support potential market clearance
of the Aethlon Hemopurifier&reg; as a treatment for Ebola virus. The Hemopurifier is a first-in-class bio-filtration device designed
for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets
antiviral drug resistance and could serve as a first-line countermeasure against Ebola and other viruses that are not addressed
with proven drug therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Humanitarian Use Device (HUD) is intended to benefit patients
by treating or diagnosing a disease or condition that affects or is manifested in fewer than 4,000 individuals in the United States
per year. If the HUD application is designated by the FDA, Aethlon may then submit a Humanitarian Device Exemption (HDE) marketing
application to the Center for Devices and Radiological Health (CDRH) for marketing review. There is no assurance that Aethlon will
receive HDE approval to market the Hemopurifier as a treatment for Ebola virus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aethlon
Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer.&nbsp;&nbsp;The company's
lead product is the Aethlon Hemopurifier&reg;,&nbsp;a first-in-class device that selectively targets the rapid elimination of
circulating viruses and tumor-secreted exosomes that promote cancer progression. &nbsp;Exosome Sciences, Inc. is a majority owned
subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders.&nbsp;Additional
information can be found online at&nbsp;</FONT><FONT STYLE="font-size: 10pt"><U>www.AethlonMedical.com</U><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">and connect with the Company on Twitter, LinkedIn, Facebook
and Google+.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Certain statements herein may be
forward-looking and involve risks and uncertainties.&nbsp; Such forward-looking statements involve assumptions, known and unknown
risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc.
to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
Such potential risks and uncertainties include, without limitation, that Exosome Sciences, Inc. will not be able to commercialize
its future products, including any that can be described as a liquid biopsy, that the FDA will not approve the initiation of the
Company's future clinical programs or provide market clearance of the company's products, future human studies whether revenue
or non-revenue generating of the Aethlon ADAPT&trade; system or the Aethlon Hemopurifier&reg; as an adjunct therapy to improve
patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a
broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's
ability to complete the development of its planned products, the Company's ability to manufacture its products either internally
or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's
proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability
exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual
results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events,
or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">James A. Joyce<BR>
Chairman and CEO<BR>
(Office) 858.459.7800 x301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Cell) 619-368-2000<BR>
<U>jj@aethlonmedical.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jim Frakes<BR>
Chief Financial Officer<BR>
858.459.7800 x300<BR>
<U>jfrakes@aethlonmedical.com&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #262626">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`"O`=8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HK%U3Q;HFD
M%DN;Y&E7_EE%\[9]#CI^.*Y>]^*J`E;'3&8=GGDQ_P".C/\`.NFGA:U36,3&
M=>G#=GH5%>23_$K7Y3\GV6'_`'(L_P`R:J?\)]XG_P"@G_Y`C_\`B:ZEE==]
M5_7R,7C:?F>S45XY%\0?$J-EKY9!Z-`F/T`K1M?BCJT9'VFSM9U_V0R'\\D?
MI2EEE=;68+&4WW/4J*XS3_B=I%QA;R">S;N<>8H_$<_I7566H6>HP^;9745P
MG<QL#CZ^E<=2A5I?'&QT0JPG\++-%%%8F@4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!117`^+_`!]]E9].T9PTH^66
MY'(3V7U/O_D;4:$ZTN6",ZE2--7D=#X@\7:9X>79,YFN2,K;QGYOQ]!7FFM^
M--8UHLC3FVMC_P`L820"/<]3_+VK!DD>61I)'9W8Y9F.23ZDTVOH</@:5'5Z
ML\FKB9U--D%%%%=YSA1110`4444`%36MW<64ZSVL\D,J]'C8J:AHI-)Z,#OM
M!^)DT;+!K<?FIT^T1+AA]5Z'\,?0UZ'9WMMJ%LES9SI-"_1T.1_^NOGZM30_
M$%_X?NQ/9R?(3^\A;[D@]QZ^]>7B<NA-<U/1_@=M'%RCI/5'NE%9/A_Q%9>(
MK+S[9MLJ\2PL?F0_U'H:UJ\"4)0ERR5F>I&2DKH****D84444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!117-^-?$@T#2=L##[9<Y6'_9'=OP
M_F:NG3E4FH1W9,YJ$7)F'X\\8M"7T;3)</C%S,I^[_L`^OK^7K7F]*S,S%F)
M+'DD\Y-)7U>'H1H0Y8GAU:CJ2YF%%%%=!F%%%%`!1110`4444`%%%%`!1112
M`N:7JEUH^H1WMG)LDC/([,.ZGU!KVG0-=MO$&F)=V_RM]V6,GF-O3_`UX56S
MX7\02^'M62X!8V\F%GC'\2^OU'4?_7K@QN$5:/-'XE_5CIP]=TY6>Q[?13(9
MH[B%)H7#QR*&5AT(/0T^OF3V0HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBN6^('C%_!.A0ZG'9+>&6Y6#8TFS&59LYP?[OZT`=317GGP_P#B
MC+XVUV?3)-)2S$5LT_F+.7SAE7&-H_O?I7H=`!1110`4444`%%>5^+/C+/X:
M\3WNC)HD=PMJRJ)3<%2V5#=-I]:[_P`,:RWB'PW8ZNT`@-W'O,8;=MY(ZX&>
ME`&K1110`4444`%%%%`!1110`4444`%%%%`!1110`UV5$+NP55&23T`KP_Q-
MK3Z]KD]YD^5G9"OH@Z?GU_&O2?B%JIT[PU)"AQ)>-Y(QV7JWZ<?C7D%>[E=&
MR=5^B/,QM2[4$%%%%>R<`H!9@J@DDX`'>NVT[X8:A=6JS7=Y':.XR(MA<@>_
M(P:/AQX>%[?'5[E,PVQQ$".&D]?P_F1Z5ZC7C8W'2ISY*;VW._#893CS3/./
M^%4R_P#083_P'/\`\51_PJF7_H,)_P"`Y_\`BJ]'HK@_M#$_S?@O\CJ^JTNQ
MYQ_PJB7_`*#"?^`Y_P#BJ/\`A5$O_083_P`!S_\`%5Z/11_:&)_F_!!]5I=C
MS2?X57:Q$V^J0R/V5XR@/XY/\JXJ^L;G3;R2TNXFBFC.&4_YY%>I^/?B!9^!
M;2W:2U:\NKICY5NLFSY1C<Q;!P.1VY_/&'K5QIOQ`\()XDT=6\^T)66-@-Z@
M<LK8],[A[$^M=>%S";J*-5W3.>OA8J/-#H<!1117NGG!1110`4444`>F_#/7
M3<V<NCSME[<;X23U0GD?@3^OM7=UX1X?U0Z/KEK?`D+&X\P>J'AOT)KW8$,`
MP.0>017S68T?9U>9;,];"5.:'*^@M%%%><=@4452UC4!I.B7VI&/S!9VTD^S
M.-VQ2V,_A0!=HKY^D^+_`(\UZ<VVC6L44G54LK0S28SWW;L_D*F5_C1J:"8#
M4T'H5C@//^R=I_2@5SWNBOG:^\4?%;PN"VHSZA!&#S)/;I)'D]MY4CMZUUW@
M3XSOJ^IP:3XAMHHI;AQ'#=0`JFX]`ZDG&3W'<C@=:`/6Z**YWQ/XQLO#BB+;
M]HO&&5A5L;1ZL>U73IRJ2Y8J[%.<8*\CHJ*\H3Q;XQUZ<KIRLH'5;:`$+]6.
M<?G4\D_Q%L4,[BZ91R<)'+^@R:[7@)K24XI]KG-];B]5%V/4**\[T/XF,TRV
M^M0(JDX^T1`C;_O+_4?E6_X\U^ZT'P+?:UI<D1GB6(Q.PWJ0TBKGWX8US5L/
M4HNTT;4ZL*BO$Y7XP^,]=\*R:7#HMVMK]I61I&\I7)V[<?>!`ZFK?P9UO4]>
M\/ZC=ZK?37<WVT@-*V=HV+P!T`]A7BGBCQEK'B^6WDU>6)S;*PC\N,)C.,]/
MH*L>&?'^O^$K*6TTF:%(II/,821!OFP!U^@%8&A]3UYE\>O^1'L_^PDG_HN6
MN0\-_%[Q9J7B?2K"YGM6@NKR*&0"``[6<*<'Z&NO^/7_`"(]G_V$D_\`1<M`
MSC/@+_R/%Y_V#7_]&15]`5\\?!.^M=,\5:G?7LRP6\&E2/)(W10)(JT?$_QT
MU.ZF>#PW;I96XX%Q.@>5O<*<JOT.?PZ4`>[45\PW'Q`\>R1_:Y=8OTB;I(L8
M1#],`"KFF?&3QEI\P::^BOX@,>5<PKCZY4!L_C0(^DJ*Y?P/X[T_QOI\DMM&
MUO=6^!<6SG)3/0@]U.#SQTZ5U%`SY@^*G_)2M8_ZZ)_Z+6O=_AK_`,D[T7_K
MW_J:\(^*G_)2M8_ZZ)_Z+6O=_AK_`,D[T7_KW_J:!'4445YCXV^,MEH-S+IN
MAP)J%[&=LDSD^3&W<<<L1WP0/?J*!GIU%?-A^)'Q#UZ:2.RO;E^<^58VJ_(/
MJJEL<=S39_&_Q*T'#7M[J=IO.!]LM1@G'0;UH$?2M%>,^%?CL7N%MO%%I''&
MW`O+56^7I]Y.2>YROY5[%!/#<P1W%O*DL,JAXY$8,KJ1D$$=010,DHJKJ=P]
MII5W<Q8\R&!W7(R,A217AOASXN^+=2\3Z587-Q;&"ZO889`MN`2K.`>?H:`/
M?**\M\=_&2+0;Z72M!MXKR[A)6:>4DQ1L#RH`P6/7/(`/KSCSB3XD>/]5+/%
MJMVRH<D6T"J%]OE7^=`'TS17S#:?%7QM9L-FN22*#DK-$CY]LE<_D:]1^'_Q
M>B\2WT>D:U;Q6=_+GR98L^5,?[N#DJV.G)!YZ'`(!Z;1110!Y7\3[XS:[!9@
M_+;0Y/LS')_0+7%UL^+KC[5XLU*3.<3F/_OGY?Z5C5]=AH<E&,?(\&M+FJ-A
M4]C93:C?0V=NNZ69PBCZ]_I4%>C?#/0=J2:W.G+9CM\CM_$W]/SHQ-94:;F%
M*FZDU$[;2M-ATC3(+"W'R0IC./O'N3]3DU<HHKY)MR=V>ZDDK(****0PJ.XN
M(;6WEN;B18H84+R2.<!5`R23Z`5)7E7QO\6_V?I,?ARTE(N+X![G:>5A!X'_
M``(C\E/K0!Y-XU\3R^+O$]SJK[EA)\NVC;K'$/N@]>>I/N36S\*/%:^&O%2P
M73A=/U(""XW=%;^!C]"2#VPQ-<110![#XOT(Z#KLL2+BVF_>0'MM/;\#Q^58
M5=?X=O\`_A8GPW$+GS-:T7"$DY:08^4Y/)W*,'U92:Y"OJ,%7]M2UW6YXF(I
M>SGILPHHHKN,`HHHH`*]M\'7QU#PK8S,<ND?E-D\Y4[?Z`UXE7J7PNN#)H5U
M;DY\JXR/8%1_4&O,S.%Z/-V9UX.5JENYVU%%%?.'KA4%[9V^HV4UG=Q"6WG0
MI(A)PRGJ.*GHH`KV.GV6F6PMK"T@M(%)(B@C"*/7@58KG-=\?^%_#DC0ZCJT
M(N%.#!%F20'K@A<[?QQ7"ZI\?K%`5TC1)YB1]^ZD$8!_W5W9_,4`>KWD5M-9
MS17J1O;/&1,LH!0ICG.>,8KY`O#;IJ$YL7<VZRMY#-PVS/RD^^,5W5WXA^(?
MQ-!LK6WE:S8@/%9Q^5!D?WW)_1FQP.*X6^LY-/U"YLIBIDMI6B<J<@E20<>W
M%`CZTU#5%TS0)=3FP?*A#XZ;F(X'XD@5Y#H]C<^*_$J13RLS7#F2>3N%')_P
M'X5W?Q!G:+P5;(O2:6)&^FTM_-17!>'-0U;3;R2XTBU:>8Q[&Q"9,*2#T'3I
M7N8"FXX>4X_$SS<3*]51>R/:;*RMM.M([6TA6*&,855'^<GWJQ7F/_"7>-_^
M@8__`(!/1_PEWC?_`*!DG_@$]<;P-5N[DOO.A8J"T2?W"_$S1(;2X@U6WC""
MX8I,!P"_4'ZD9S]*U_ACJLEWI-QI\K%C:.#&3V1L\?@0?SKEM:U+Q7K]FEK?
M:7/Y:2"0;+1P<@$?U-;GPSL+RSO;YKJTG@#1J`98RN>3TS795C;!\LVFU_F<
MU.5\1S16C.6_:"_X_-#_`.N<W\TK:^`?_(J:C_U_'_T!*Q?V@O\`C\T/_KG-
M_-*VO@'_`,BIJ/\`U_'_`-`2O#/3/4J\R^/7_(CV?_823_T7+7IM>9?'K_D1
M[/\`["2?^BY:!GA>EVE[J6H1:98;C-?.L`0,0'RP(#>V0#[8SVKZ8\'_``^T
M3PA9Q""VCN+\+^]O94!=F[[?[H]AVZY/->/?!&PCO/B`)GZV5I),GU.U/Y.:
M^BJ`"O*_B]X`TV?0;CQ%IMJMM?6F'G6%`%G0GDD#C<,YW>@(.>,>J5@>//\`
MD0M<_P"O&7_T$T`>#?"/49-/^(VGJLA2.Z#P2C^\"I('_?04_A7TQ7RQ\.?^
M2A:)_P!?2_UKZGH`^8/BI_R4K6/^NB?^BUKW?X:_\D[T7_KW_J:\(^*G_)2M
M8_ZZ)_Z+6O=_AK_R3O1?^O?^IH$9/Q>\6S>&O"RVUC*T5]J3&*.13AHT`^=@
M?7D#L1NR.E>3_"_P/'XSUV0WI8:;8A7N`IP9"<[4SU`.#DCL.Q(-:_QYNGD\
M96=MO;RX;%2%/0,SODCZ@+^5=S\#;+[-X#:X(YN[R23..P"KC\U/YT`=]8Z?
M9Z9:):6%K#:V\?W8H4"J/7@5-)&DL;1R(KHXPRL,@CT(IU%`SPCXO?#JUT-%
M\0:+`(;.239=6Z`[8F/1E'92>,=`<8Z\:7P*\52R?:/"]T^Y(T-Q:$_PC/SI
MU]6#`8_O>U>B>/K2*]\`ZY%,H95LI)0#_>1=Z_JHKYY^'%^=.^(6B3@$[[H0
M\#_GH#'_`.S4`?3.N?\`(!U#_KUE_P#037R+;7$UG=175O(8YH7$D;KU5@<@
MC\:^NM<_Y`&H_P#7K+_Z":^2M+LCJ.K6=B&VFYG2$-Z;F`_K0(]I^%?PQTY=
M'M_$&NVB75S=*);:"4!DCC/W6*]&)!SSTXZ&O65544*H"J!@`#@"D1$BC6.-
M0J(`%4#@`=J=0,Y_Q7X,T?Q=I\D%]:QBYV$0W83]Y$V.#GJ1G^$\&OEV>&[T
M;5I(68PW=E.5)4\I(C8X/L17V%7R9XS_`.1XU[_L)7'_`*,:@#ZHTF^75-'L
MM0086[MXY@/0,H;^M6ZQ?!G_`"(^@_\`8-M__1:UM4`>!ZNV_6KYR,%KB0_^
M/&J=7=90QZY?QG^&YD'/^\:I5]G#X4?//<OZ+I4VM:M!80Y!E;YFQ]Q>I/Y5
M[G:VT-E:Q6L"!(H4"(H[`5R/PXT'[#IC:I.N)[P?N\_PQ]OS//T`KM*^=S#$
M>TJ<JV7YGJX2ER0YGNPHHHKSCL"BBB@"IJNIVNC:7<ZE>R".WMHS([>P[#U)
MZ`=R:^3_`!#K=SXCUZ\U>[XENI"VT=$7HJ_@H`_"O4_CKXJ??;^%[5R$P+B[
M(/WO[B=?JQ!']WTKQN@`HHHH`Z;X?^*W\(>*K>^9C]DE_<W:^L9/)Z'E3AN.
MN,=Z]&\>:&NF:Q]LM@#:7V9$*]`W\0_7(^OM7B=>U?#S5$\;^!;CPK=N/[1T
MQ0]HS$9:,<+[_*?E/'`9>]=>#K^QJIO9[G/B*7M(:;G,T4Z2-XI&CD4JZ$JR
MD8((ZBFU]4>*%%%%,`KT7X4$[=57)P/)('_?=>=5Z-\*$8)JCD?*3$!]1O\`
M\17#F'^[2^7YHZ,+_&7]=#T*BBBOESV@KQKXR?$"_LK_`/X1C2+A[;:BO>31
M,5<D\B,'L,8)QUR!TSGV6OFKXQVTT'Q*U&26,JEPD,D1/\2^6JY_[Z5A^%`#
M_`'POOO&:F_N)C8Z6C[?-VY>8@\A![=-QX!['!Q[-HGPQ\(Z$JF'28KJ8``S
M7G[YB1WP?E!_W0*I?"#5[#4/`-G:6LD8N+'='<0@_,A+,0Q'HP.<],Y&<@UW
M-`"*JHH50%4#``'`%?)'BC_D;-8_Z_I__0S7UQ7R/XH_Y&O5_P#K^G_]#-`'
MT+X_MVG\$P2+T@DBD/TP5_\`9A6!\+KE8]<NK8\>=;Y'N5(X_(G\J]#FL8]2
MT(V4WW)[<(2.V1U_"O&D-_X4\1*S+MN;.3IV<?X$?SKV<':MAYT>O]?J>=B/
MW=6-3H>Z45EZ)X@T_7K59;2=?,QEX6/SH?<?UK4KR)1E%VDK,]",E)7045%<
M75O:1&6YGCAC'5I'"C\S3;.]M]0M5NK242PN2%<=#@D']0:5G:_0+J]CQK]H
M+_C\T/\`ZYS?S2MKX!_\BIJ/_7\?_0$K&_:"!^UZ$V#@I.`?Q2IO@+KMG%!J
M&A33)'<R2B>!6.#*-N&`]2-H./?V-(#V6O,OCU_R(]G_`-A)/_1<M>CW%U;6
MB![FXBA5B%!D<*"3T'-><?'K_D1[/_L))_Z+EH&<9\!?^1XO/^P:_P#Z,BKZ
M`KY_^`O_`"/%Y_V#7_\`1D5?0%`!6!X\_P"1"US_`*\9?_036_6!X\_Y$+7/
M^O&7_P!!-`,^=_AS_P`E"T3_`*^E_K7U/7RQ\.?^2A:)_P!?2_UKZGH$?,'Q
M4_Y*5K'_`%T3_P!%K7N_PU_Y)WHO_7O_`%->$?%3_DI6L?\`71/_`$6M>[_#
M7_DG>B_]>_\`4T`>5?'JSDB\7V-WL(BGL@H;U97;(_)E_.NU^!E^+KP/+:%A
MOL[MUVYY"L`P..W);\C5[XM>$9/$_A7SK.(R7^G$S0HHRTBD?.@'J0`1ZE0.
M]>._#7QM_P`(9K[27`9M.O%$=TJC)7'W7`[D9/'H3WQ0!].454TS5=/UFR2]
MTV\BNK=QP\39'T/H?8\BIKBX@M+>2XN9HX88U+/)(P55'J2>`*!F%\0;V*P\
M`:Y-,<*UG)"/]Z0;%_5A7SY\-K#^T?B'HL/9+@3?]^P7_P#9:ZCXN?$6W\1.
MN@Z/)YEA;R;YKA3Q.XX`7U49Z]SR.`"=WX&^$IK6*X\3WD93[0GDVBMW3.6?
M'N0`/HWJ*!'J6N?\@#4?^O67_P!!-?+7@S_D>-!_["5O_P"C%KZEUS_D`ZA_
MUZR_^@FOEKP9_P`CQH/_`&$K?_T8M`'UG1110,*^3/&?_(\:]_V$KC_T8U?6
M=?)GC/\`Y'C7O^PE<?\`HQJ`/IGP9_R(^@_]@VW_`/1:UM5B^#/^1'T'_L&V
M_P#Z+6MJ@#Q+QG;?9?%VH)MP&E\P>^X!OZTSPMHC:]KD-H0?)7]Y.1V0=?SZ
M?C70_%&P,6JVE^H^6>(QL<?Q*?\`!A^5=1X#T'^QM#6:9,75YB23/55_A7\C
MGZDU]#+%<F$C);M6/)C0YJ[B]D=*B+&BHBA548``X`IU%%?/'K!1110`52U?
M4X='TN>_G^["N0N?O'L/Q-7:\N^).O?;-032('S#:G=+@\-)Z?@/U)]*Z<+0
M=:JH].IC7J>S@WU/-O%\<VL&;5)3ON0Q=SZJ>OY=O;-<;7HA&00>0:XC5[`V
M%^\8'[MOFC/MZ?ATKT,RPRC:K%:;/]#EP=6_N,I4445XQZ`5L>%/$,_A;Q)9
MZO!N(A?$L8/^LC/#+^73T.#VK'HH`]T\>:;;R/;>(].8266I(K[EZ;B,@_B/
MU!KCZV_A)K4&O:!>^!]1<`A6ELF..`3E@/<-\WOENPK*O+2:PO)K2X7;+"Y1
MA[C^E?1Y=B/:4^1[K\CR,52Y)\RV9#1117IG(%>J?#"V,7AZ>=ACSK@X]P`!
M_/->5U[EX6L#IGAJQM6&'$0=P>S-\Q'YFO+S.=J*CW9V8.-ZE^QK4445\Z>L
M%<CX^^']CXXLH]TOV2_M\^1<A=PP>JL.X_4'GU!ZZB@#YS;X5_$'0+XS:9$6
M=%P+FPO`AY[#)5OTK0_L?XSSQ>1YNJ!<`9^W1H>/]K>#^M>^44`<%\+?"^NZ
M%:ZC>^)))6U&^D0$2SB9@B`XRP)Y)9N_85PFM?!;Q3J&N7][#+IXBN+F25-T
MS`X9B1GY?>O>**!6(X$,=O'&V,J@!Q["LKQ#X7T_Q'`!<@QSH,1SI]Y?8^H]
MJV:*J$Y0ES1=F*45)69Y->?#C7[*7?9-%=!3E6CDV-^1QC\S3/\`A'O'3*$V
MWNWT-X,?^A5ZY17H+,JMO>2?R.7ZG#HV>2Q?#SQ+>OONC#$QZM//N/\`X[FO
M3='L/[+T>TL<AC!$%8J.">Y_/-7:*YZ^*J5TE+9&M*A"D[HY/XA^"(_&^AK;
MI*D%];,9+69QQDC!5N^T\9QW`/.,'Q&Y^$GC>WF9!HWG*"0'BN(RK>X^;/Y@
M5]-45RFY\]^%/A/XNB\2Z9>7^F1VUK;W44TK2W"'*JP)`"DG.!Z5ZE\3_">H
M^,?#=OI^F/`LT5XLQ\]RHVA'7L#SEA7944`>6?"_X;:YX/\`$EQJ.IR6;0R6
M;0J(9&9MQ=&[J.,*:]3HHH`*RO$^FSZQX8U/3;8H)KJV>*,N<+DC`R:U:*`/
M$O"/P@\2Z'XKT[5+N6P,%K,)'$<S%L>PVU[;110!XOXW^$OB/Q#XPU#5K*6Q
M%O<NI022L&X11R-I[BO3O!^D7.@^$].TN\,9GMHMCF,Y7.2>#Q6U10*P5YMX
MW^#NG^(KB;4](F73]0E.Z1&&89FYY('*DG&2,_3))KTFB@9\W2_"?Q[I-V7L
M[+S"GW;BTNT7/TR0WZ4V7X:_$75YE-[87,Q!QYEU>HVW/?E\]NU?2=%`'D'A
M3X%Q6MPEWXFNX[K8<BSMB=A]-SG!/T`'U/2O7(HHX(DABC6..-0J(@P%`X``
M["GT4`5M2MWN]+N[:,@/-"\:YZ9*D"O$_#WP:\4:7XDTO4;B73S#:7D4T@29
MB=JN&./EZX%>ZT4`%%%%`!7A7B'X,^*-4\2:IJ%O-IXAN[R6:/?,P.UG+#/R
M]<&O=:*`,[P]83:7X;TS3K@J9K2SBAD*'*EE0*<>V16C110!0U71[368X([Q
M-RP3+,H]2.Q]CFK]%%-R;20DDG<****0PHHHH`R?$NM)H.B37A(\W&R%3_$Y
MZ?X_05X?)(\TCRR.7=V+,S'))/4FNH\?Z]_:VM&UA;-M9$HN/XG_`(C_`$_#
MWKE:^FP&']E2N]V>-BJO/.RV05G:Y8?;K!BBYEB^9,=3ZC\?YXK1HKLJ0C4B
MXRV9A"3A)21YW16GK]A]COBZ#]U-EE]CW'^?6LROD:M-TIN$NA[L)J<5)!11
M1699<TC5;O0]6M=4L7V7%K()$/.#CJ#CJ",@CN":]L\80VNOZ)8>,=+&8;J-
M1..I4]!G'<$%3[@5X/7J7P:\1Q/-=>#M3.ZSU%6:WW'[LF/F4<<9`SUX*^K5
MOAZSHU%-&5:FJD'$HT5=U?3)M'U2>PG'S1-@-_>7L?Q%4J^MC)22:/"::=F:
M_A;23K7B&UM2NZ(-YDWIL7D_GT_&O<:XWX<Z"=.TEM1G0B>]`*@_PQ]OSZ_E
M795\WF%;VM6RV6AZ^$I\D+O=A1117GG6%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!6'XK\1-X:T^*Z6U%QYDOE[2^W'!.>A]*W*XGXI?\@"T_Z^A_Z"
MU=&&A&=:,9;,RK2<:;:-KPKXD7Q+I\MQY`MY(I-C1A]W&`0<X'O^59OBCQT/
M#VJ+8Q62W+>6'=C+MVDYXZ'M@_C67X?8>'/B#J.ER$1V]T&=,\`8^=?R!85S
MM\IUJTUOQ'*IP9TCASVR?YA0H_&N^GA:3K-M>Y96^>WZG)*O-4TD_>UO\CT:
MY\2M;^#5\0?90S&-'\G?@?,P7KCW]*PK;Q_K%Y")K7PK<3QDX#Q%V4_B$I=1
M_P"20)_UPA_]&+6?X2UCQ!9Z#'#I^A?;(`[$2^9C)SR*F%"G[.4N5-J36KMI
M]XY59<T5>VG8Z_0-:O\`5;>YEOM(FTYH<;5E##?P>F0*YNT^(VIW^_[%X:EN
M=F-_DNS[<],X7CH:Z[3+J^O-),VH6?V.<[@8MV<#L:XSX3_\Q7_MC_[/6<(T
M^2I.4=K:7?H7*4^:$5+>Y>@^(WD7BV^M:-<:<&Z.V21[E2`<?3-;OB3Q`-"T
M9=2BA6Z5G55&_`(()SG!K-^(]O!+X5>611YD,J&(]P2<$?D3^5<]J<LDWPDT
MYI"2PE"C/H&<#]`*J%&E54)J-DW9H4JE2'-%N^E[G=:3K":AH$.K3JMLCQF1
MP6R$`)SS^%<U)\0IKV\:WT+19[X)U<Y''K@`X'UQ5'4)I(OA':"/($FU'(]-
MY/\`05T'P_M8(/"5K)$`7G+/(P'5MQ'Z``5+I4J<)5)*_O-)#4YS<8)VTNQ^
M@^(-6U#46M-2T*6Q7RRZRG=M)!`QR/<]^U7_`!!K46@:1+?R)YA4A4CSC>QZ
M#^OX5IUY=\0=:AO?$$&FN[FSLV'G>7R2Q^]CMD#CZYK.A3CB*R2C9=2ZLW2I
MZN[.F\+^-QXAU"2RFLQ:R"/S$_>;MX[]AV(-:'BKQ`WAO3([Q;87!>81;2^W
M&58YS@_W:\YU+Q'I_P#PE=IK6D030K"$$D<B*,X^4XP3U7BNK^)<L=QX4LYH
MF#QR72,K#H04<@UT3PL57I^[:,NAC&M)TY:W:ZG4Z1?G5-)MKXQ^69XP^P'.
MW/O5VL?PE_R*FF_]<%K8KS:B49M+N=D&W!-A4-Y/]ELI[@+N\J-GVYQG`SBI
MJIZM_P`@>]_Z]Y/_`$$THJ\DBI.R9E>$O%#>)H+F1K06WD,JX$F[.<^P]*Q;
M3XF1RZLEG=V"V\)D,;3>=G;V!(QTS3/A5_QYZC_UT3^1KG=$\.CQ#%KD<8Q=
M0,KP'U.6ROX_X5ZWU>@JE136BM\KGGNK5<(.+U=_P/5=4O3IVE75\$$GV>)I
M`N<;L#.,U4\.:W_;NC+J+PBWW,P*[]P&#US@5R&C>(6O_!6JZ3>$B\L[20#?
MP60`C\QT/X4:;-);_"*[>+.XETX]&<*?T)KG>%Y8N+WYDK^3-?;WDFMK-FC>
M?$(2WYLM#TR74G!^^,@'W``)(]SBKFC^)-:N]5AL]1\/36D<V[$_S;5(!//&
M.<>M5?AE:6\7AZ2Z0`S33,)&QR`,87^OXUV537=&G)TXPVTO=W*I*I-*;E\@
MHHHKA.H*Y[QKKW]AZ$YB?%U<9CA]1ZM^`_7%=`2`"2<`=37BOC#73KVNR2QM
MFVA_=P#_`&1U/XGGZ8KNP.']M5UV6YS8FK[.&F[,+.31117U!XP4444`5-4L
M1J%B\/1Q\R$]F'^<5PS*58JP((."#VKT2N<UK0YYKWS[.(.)!EQN`PWX^O\`
MC7DYCAG42J05VCNPE91;C)Z'/45H_P!@:I_SZ_\`D1?\:/[`U3_GU_\`(B_X
MUXWU>M_(_N9Z'M:?\R^\SJDMKF:SNHKJVD:*:!UDC=>JL#D$?0BKO]@:I_SZ
M_P#D1?\`&C^P-4_Y]?\`R(O^-'U>M_(_N8>UI_S+[SVC6)X/''@JS\66*J+F
MW7R[V)>J$?>'X$Y'^RV:S?!GAEM?U,/,I%E;D-*W9CV0?7O[?A53X+IK=EK%
MYI=Q8/+I-Y$3.2P*1.`<$C/\0RI`Y/'85[+INF6FD6*6=E%Y<2=NI)[DGN:Z
MXXRI1HNDU9]/)',\/&I4YT]"T`%4*H``&`!VI:**\T[0HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"N2^(FG7FI:-;165M)<.MP&*QKD@;6Y_6N
MMHK2E4=*:FNA%2'/%Q9PGQ#T"^O;JTU#3+>664(T4HB'..H_FP_*DN_#MW;_
M``UBT^"U>2[D=99(U7+;B<G(]A@?A7>45O'%S4(P_E=S)X>+E*7<X^^TV]D^
M&"Z>EK(UV(8AY(7YLAU)X^@K)T#4/$^@:4EA'X:FF569M[`@\G/I7HU%$<5[
MKC**:;OU!T-4T[65C$T/4M4U2UN3J6EM8.G$:G/SY!]:X?PN/$OAG[5Y7AZ>
M?[3LSN4C&W/_`,57J=%*&)45)<JM*VFO0)47*SYM4><W^G^+?&5Q##?6BZ=8
MHV[#<`=LD9RQQG'0?2MGQAHLO_"'0:9I=M)-Y$D85$&3@`\UUM%-XN7-%I)*
M.R#V"L[N[?4YK2]"^V^`X-(OXWA=HB&###(VXD''UQ7/:8OBSP89+1=,.I61
M;<GE9;!]1C)'N"*]&HI1Q+7,I)--WL-T%HT[-'(VGB;Q#=BXD?PW-;QQ0LR!
ME8L\G`4#('<\\=`:J>`?#MW;3WFJ:M;NES*VQ!,OS<\LWXG'Y&NYHH>(M&48
M12N"H^\I2=['/>,M#&K^'9HH(0UQ$1+$%')(ZC\03^.*Y.[T_7+WP#:Z;+IM
MS]IM+P!5*')CVM@_@3C\J]-HITL5*G%1M>SN*=!3;=[75C@-+UOQ3I>F6]BO
MA>618$"!CN!./PK3O_&-WI6@V][?:48[N>8QBU9RI`'\6<?3\ZZRJ-[H^GZA
M=VUU=VXEFM&W0DLP"'(.<`X/0=?2CVU*<KSA]U_\Q>RJ1C:,B>SDGFLX9;F$
M03.@9X@V=A/;-,U.-Y=+NXXU+.\#JJCJ25/%6J*Y;V=SHMI8XOX<:7?:9:WR
MWUI+;EW0J)%QG@TSP!I5_IVH:L]Y:2P+*R^677&[ENGYBNWHKIGBI3Y[KXK?
M@8QH*/+KM?\`$\\\<>$[QM0&JZ-!([7`*7$<0YR1@MCT(R#_`/7K:\):/)_P
MA9TS4[=XO-,BNC##`$]:ZFBB6*G*DJ;Z=>H*A%3<UU/.+&P\4^"+J9+.S_M.
MPD.XB,$Y/K@<J<>Q'UK>TCQ'K^IZI#!/X=EL;8D^;+,&X`!(QD#O@5U-%.>)
M52[G!7[ZBC1<-(R=NQSUQJ6OIXMBLH;$-I;;=\_EDD?+SSG'7VKH:**YYR4K
M65K&T8M7UN<C\0]>_LS1_L$#XN;T%>.JQ_Q'\>GY^E>2U[QJ^AZ=KEOY-_;B
M3'W''#I]#7G&M_#C4[`M+IQ^W0#G:.)%'T[_`(?E7LY?B*,(<CT9YV*I5)2Y
MMT<=13Y8I8)6BFC>.13AD=2"/J*97LG`%%%%,`HHHH`***T-+T+4]9DV6%G)
M*,X+XP@^K'BIE)15Y.P)-NR,^N@\->$+_P`0RB0*8+,'YYV'7V4=S^E=?H/P
MUM;0K/J\@NI1SY*9$8/OW;]!]:[=$2-%1%"(HP%48`%>1B<R2]VE]YWT<&WK
M,J:5I-GHMBEG91".->2>I8]R3W-7:**\-MR=V>DDDK(****0PHHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`*E_I6GZFF
MR^LX;@#H70$CZ'J*YF]^&>BW!+6TEQ:GLJOO4?GS^M=C16U.O5I_!)HSG2A/
MXD>:S?"JY4_N-5B<?[<17^1-5/\`A5VN?\_5A_W\?_XBO5:*ZEF.(77\#%X2
MEV/+8OA;JY;][>V2KZJSL?\`T$5HVOPJC!!N]59AW6*(+^I)_E7H-%3+,,0^
MMOD"PE)=#G=/\">']/(86?VEQ_%<-O\`TZ?I70(B1H$10JC@*HP!3J*Y)U)U
<'>3N=$81C\*L%%%%04%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
